Back to search
FDAFDA · Food and drugs·Recall number D-0570-2023

Gabapentin Tablets, USP 600 mg, packaged in Cartons of 100 tablets (10 tablets per blister pack x 10), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. East Windsor, NJ 08520 Distributed by: Major Pharmaceuticals 17177 N Laurel Park Dr., Suite 233 Livonia, MI 48152 USA, NDC 0904-6823-61

Published May 17, 2023 · Recall initiated: April 24, 2023

Summary

FDA records drug Class III recall D-0570-2023, published May 17, 2023 and initiated April 24, 2023. Recalling firm: The Harvard Drug Group; Status: Terminated; Reported quantity: 3984 cartons; Lot: Lot: T04468, Exp 10/2024. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Product mixup: one foreign tablet found in product.

What to do

Voluntary: Firm initiated · Letter

Get an email if GABAPENTIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
GABAPENTIN
Manufacturer
The Harvard Drug Group
Distributor
USA Nationwide
Lot
Lot: T04468, Exp 10/2024
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Gabapentin Tablets, USP 600 mg, packaged in Cartons of 100 tablets (10 tablets per blister pack x 10), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. East Windsor, NJ 08520 Distributed by: Major Pharmaceuticals 17177 N Laurel Park Dr., Suite 233 Livonia, MI 48152 USA, NDC 0904-6823-61 recalled?

Yes. FDA published recall D-0570-2023 on May 17, 2023. Reported hazard: Product mixup: one foreign tablet found in product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: GABAPENTIN.